News | Proton Therapy | September 17, 2019

IBA Gathers Experts on Flash Irradiation During ASTRO

Key opinion leaders in the field of proton therapy shared their latest insights and research on Flash irradiation during IBA’s 3rd Victoria Consortium Meeting and IBA’s symposium on proton therapy

IBA Gathers Experts on Flash Irradiation During ASTRO

September 17, 2019 — IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago.

In addition, during IBA’s annual symposium on proton therapy, Amit Maity, M.D., executive vice-chair radiation oncology, Perelman School of Medicine, University of Pennsylvania, also shared the latest insight on proton Flash radiation therapy for gastrointestinal (GI) malignancies.  

Flash therapy has the potential to dramatically change the landscape of radiotherapy and patient cancer care, making it more effective and more accessible than conventional radiotherapy. Flash irradiation is a fast and powerful treatment that delivers a high dose of radiation at an ultra-high dose rate. This novel technique could potentially shorten treatment time from 6-8 weeks to less than a week, and has the potential to reduce side effects for patients.

IBA is collaborating with several leading proton therapy centers in their research work to better understand the mechanisms of Flash irradiation. This early development work enables IBA today to deliver Flash irradiation on both its current single- and multi-room proton therapy platforms in a clinical environment in research mode, as demonstrated in March 2019 at the University Medical Center of Groningen, The Netherlands, and in June 2019 at the Rutherford Cancer Center Thames Valley in Reading, England. 

Alexander Lin, M.D., associate professor of radiation oncology and chief of the Head and Neck Oncology Service at the Hospital of the University of Pennsylvania, Philadelphia, commented, “Flash is a very exciting opportunity and we believe that proton therapy can be a very suitable modality to achieve the desired outcomes. We are at a stage where more research is needed to better understand the mechanisms of FLASH irradiation, and we are very excited about our current research program at Penn Medicine. Coordinating our efforts with other centers is key, and IBA’s Victoria meeting offered a great forum to share our insights.”

Flash therapy is currently under research and is not available for sale.

For more information:

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.